Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...